NeOnc Technologies Enhances NEO100 Potency with AI-Driven Ultrasound Findings.

NeOnc Technologies has announced preclinical findings from a research collaboration at the University of Southern California. The study shows that ultrasound enhances the potency of NEO100, a brain-penetrant therapeutic for CNS cancers, driving strong antitumor effects across multiple primary and metastatic brain tumor types. The findings were published on bioRxiv and utilize AI-driven, 3D-bioprinted New Approach Methodology (NAM).